Amicus Therapeutics Inc
NASDAQ:FOLD
Amicus Therapeutics Inc
Tax Provision
Amicus Therapeutics Inc
Tax Provision Peer Comparison
Competitive Tax Provision Analysis
Latest Figures & CAGR of Competitors
Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
Tax Provision
-$6.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Tax Provision
-$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Tax Provision
-$617m
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Tax Provision
-$582m
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Tax Provision
-$760.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Tax Provision
-$184.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
6%
|
See Also
What is Amicus Therapeutics Inc's Tax Provision?
Tax Provision
-6.6m
USD
Based on the financial report for Mar 31, 2024, Amicus Therapeutics Inc's Tax Provision amounts to -6.6m USD.
What is Amicus Therapeutics Inc's Tax Provision growth rate?
Tax Provision CAGR 5Y
-35%
The average annual Tax Provision growth rates for Amicus Therapeutics Inc have been -20% over the past three years , -35% over the past five years .